Martin Auster
Stock Analyst at Raymond James
(3.93)
# 640
Out of 5,113 analysts
56
Total ratings
55.81%
Success rate
11.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Strong Buy | $40 | $20.49 | +95.22% | 1 | Jan 8, 2026 | |
| SEPN Septerna | Initiates: Strong Buy | $38 | $23.66 | +60.61% | 1 | Dec 19, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $77.49 | -8.38% | 2 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | n/a | $72.46 | - | 2 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $80.01 | +34.98% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $222.45 | +21.83% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $17.70 | +97.74% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $349.58 | +21.29% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $56.68 | +111.71% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $24.44 | +329.62% | 7 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $10.48 | +148.09% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $6.55 | +1,732.06% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $725 → $300 | $24.45 | +1,126.99% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $29.40 | +97.28% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $467.30 | -58.06% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $1.37 | +7,053.28% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $155.89 | -61.51% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $43.13 | +50.71% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $21.31 | +242.56% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $23.02 | +238.84% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.46 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $8.04 | +434.83% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $13.82 | +51.95% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $47.45 | -66.28% | 1 | May 7, 2020 |
Evommune
Jan 8, 2026
Initiates: Strong Buy
Price Target: $40
Current: $20.49
Upside: +95.22%
Septerna
Dec 19, 2025
Initiates: Strong Buy
Price Target: $38
Current: $23.66
Upside: +60.61%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $77.49
Upside: -8.38%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $72.46
Upside: -
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $80.01
Upside: +34.98%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $222.45
Upside: +21.83%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $17.70
Upside: +97.74%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $349.58
Upside: +21.29%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $56.68
Upside: +111.71%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $24.44
Upside: +329.62%
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $10.48
Upside: +148.09%
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $6.55
Upside: +1,732.06%
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $24.45
Upside: +1,126.99%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $29.40
Upside: +97.28%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $467.30
Upside: -58.06%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.37
Upside: +7,053.28%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $155.89
Upside: -61.51%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $43.13
Upside: +50.71%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $21.31
Upside: +242.56%
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $23.02
Upside: +238.84%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $3.46
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $8.04
Upside: +434.83%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $13.82
Upside: +51.95%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $47.45
Upside: -66.28%